Get started
Veru Inc.Veru Inc.Veru Inc.

Veru Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

VERU trade ideas

VERU priming for an uptrend after dropping 20% in a week$VERU, an oncology bio-pharma company reported great earnings and then proceeded to drop 20% in the undertow of last week's bond market turmoil. It's earnings run-up anticipated great results as well. Looking to hold its .382 Fibonacci support level for next week in order to enter in. Happy Trading, from CJ -- aka the greatest FURU. To find out more about The Ultimate Stock Indicator on Tradingview, please check my public profile. 🚀🚀🚀🚀
NASDAQ:VERULong
by CJCHUN
2
VERU log chart. Wedge within a megaphone and channel.This is a mighty COVID treatment play. It's a coin flip whether it will break up or down out of the blue dashed wedge, but when it does. . . there are many place it can go. Options prices remain elevated even for $10 strikes (around the lower ascending channel). All depends on the Phase III trial data and analysis. Personally, I bought 1000 shares in the February pullback before the mega rally, sold into strength, and still hold 150. I've been selling $10, $15 and $17.5 strike weekly puts and taking profits at 50% to 75%. I will take any long red candles as an opportunity to sell lower-strike puts. So my bias is long, but to sell into strength. Caveat emptor.
NASDAQ:VERULong
by decaro
Stock to watch: Veru Inc (NASDAQ: VERU)NASDAQ:VERU An interesting stock to watch. The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress. The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high. Invalidation: closing below the gap. Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
NASDAQ:VERULong
by randomname11
VERU (breast cancer treatment) calendar spread ideaVERU is an oncology bio pharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer. It announced the presentation of pre-clinical data demonstrating the efficacy of oral VERU-111 in the treatment of human derived animal models of triple negative breast cancer. VERU reported on 12/9/20 Q4 earnings loss of $0.01 per share on revenue of $11.7 million. The consensus estimate was a loss of $0.05 per share on revenue of $10.6 million. That's a +80% eps surprise. Revenue grew 34.6% on a year-over-year basis. This is a speculative risky play. My idea is a VERU calendar spread: buy $10 call 1/15/21 sell $12.50 call 12/18 The worst thing that could happen this week would be a credit of $250 per spread on 12/18. Otherwise, your risk is $145 till 1/15/21. Or you can simply dca shares each day this week according to your indicators. Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny / a day, for a month it = $5,368,709. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, risk management Beware of analysts motives Emotions & Opinions FOMO : bad timing Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum www.tradingview.com
NASDAQ:VERULong
by Options360
$VERU Cup & Handle Company details Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
NASDAQ:VERULong
by DEXWireNews
1
$VERU - Bullish Trend Good YTD So FarVeru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL. SHORT INTEREST 52.79K 09/30/19 P/E Current -4.75 P/E Ratio (with extraordinary items) -7.87 Average Recommendation: BUY Average Target Price: 7.38
NASDAQ:VERULong
by DEXWireNews